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PRECLINICAL STUDIES
n Expandable Percutaneous
atheter Pump for Left Ventricular Support
roof of Concept
homas Schmitz-Rode, MD,* Jürgen Graf, MD,† Joachim G. Pfeffer, MD,* Frank Buss,*
hristoph Brücker, PHD,‡ Rolf W. Günther, MD§
achen, Germany
OBJECTIVES We sought to evaluate the performance of a newly designed percutaneous catheter with
expandable pump.
BACKGROUND The device was designed as a percutaneously insertable temporary support system for patients
with acute left ventricular failure.
METHODS The pump catheter (introduction diameter 9-F) is positioned in the left ventricle. The rotor
is driven by an external motor through a flexible drive shaft. A model circuit was used to assess
pump performance, hemolysis tests, and particle image velocimetry. The feasibility of the
catheter placement and pump operation were examined in 12 anesthetized sheep. Cardiogenic
shock was induced in seven of the animals. Cardiac output (CO) and mean aortic blood
pressure (MAP) were recorded before and during shock, and during catheter pump action.
RESULTS The catheter pump delivered a flow of 4.1 l/min at a differential pressure of 60 mm Hg. The
average modified index of hemolysis was 11.6 (optimum, 1.8). Fluoroscopically and
echocardiographically guided in vivo placement and deployment of the device were quick and
uncomplicated. Under simulation of acute left ventricular failure (CO 43  22% and MAP
55  16% of the baseline value), the catheter pump significantly improved CO to 67  12%
and MAP to 74  18%. Maximum in vivo duration of operation was 6 h (average, 3.1 
1.4 h). These animal studies revealed: 1) no significant hemolysis (average plasma-free
hemoglobin 26  4 mg/l after 3 h); 2) no thrombotic deposits at rotor or pump housing; and
3) no damage to the endocardium or aortic valve.
CONCLUSIONS A percutaneously insertable, expandable catheter pump is technically and clinically feasible.
Our first experimental results are encouraging. (J Am Coll Cardiol 2005;45:1856–61)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.071© 2005 by the American College of Cardiology Foundation
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aortality rates resulting from cardiogenic shock, which is
he state of inadequate tissue perfusion resulting from acute
yocardial infarction, and other causes of heart failure
emain in the 50% to 80% range, despite coronary interven-
ions (1). During the past two to three decades, no signif-
cant change in the incidence of cardiogenic shock as a
omplication of acute myocardial infarction has been ob-
erved (2). However, patients selected to receive early
evascularization with percutaneous transluminal coronary
ngioplasty or coronary bypass grafting during this time had
ower in-hospital mortality rates than those not selected (3).
he rate of mortality of the critically ill with acute left
entricular failure is mainly due to multiple organ failure
aused by inadequate tissue oxygenation.
Temporary left ventricular support may increase myocar-
ial oxygen supply and improve oxygen delivery to depen-
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as been no patent-licensing arrangement with any company.t
Manuscript received September 1, 2004; revised manuscript received February 9,
005, accepted February 22, 2005.ent organ systems, thereby preventing multiple organ
ysfunction and subsequent death. A non-surgical, percu-
aneously implantable device may save time and resources
ecause it could be managed by interventional cardiologists
hile executing percutaneous coronary intervention. The
urpose of this project was the development and initial
xperimental evaluation of a percutaneously insertable blood
ump for temporary left ventricular support.
ATERIALS AND METHODS
ercutaneous catheter pump. The expandable pump unit
s located at the tip of the catheter and consists of an
xpandable rotor, concentrically located within an expand-
ble housing. Both of these components are made of the
hape memory alloy (Nitinol, Euroflex, Pforzheim, Ger-
any). The middle segment of the housing, between inflow
nd outflow tracts, has a polyurethane coating that extends
o the catheter shaft as a tubing with outlet slits (Fig. 1).
he rotor is connected to a flexible shaft, driven by an
xternal motor unit with a rotation speed of 32,000 rpm.
he device is introduced via the percutaneous femoral
rterial route. A 9-F delivery sheath is placed with its tip in
he left ventricle, and the device is pushed through the
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June 7, 2005:1856–61 Expandable Percutaneous Catheter Pumpheath. Consecutively, the compressed pump unit, at the
atheter tip, is released by partial withdrawal of the sheath.
he correct positioning of the pump unit is assisted by a
uoroscopic or transesophageal echocardiography (TEE)
uidance. The inflow tract of the pump unit and the
xpanded pump housing (diameter, 6.5 mm) are placed
ithin the left ventricle, the outlet tubing in a transvalvular
ortic position, and the outflow tract (tubing slits) in the
scending aorta (Fig. 2). Before its removal, the pump unit
s compressed by withdrawing it back into the sheath. The
heath with the pump unit is removed, and the puncture site
losed via manual compression.
ydraulic and hemolysis bench test. The catheter pump
as evaluated using bench tests for compressibility and
xpandability of the pump unit, pump performance, and
emolysis. It was delivered via a 9-F sheath into a flow
odel. Within the test loop, the device was operated at
ifferent rotation speeds to determine the flow-differential
ressure relationship and the hemolysis rate. Hemolysis was
etermined by the modified index of hemolysis (MIH),
hich represents the ratio of red blood cells destroyed
uring passage through the pump to the total number of red
lood cells in the system, according to the American Society
or Testing and Materials regulations (4).
n vitro flow field studies. To assess the flow condition of
he pump (stall, vorticity, backflow) tests were performed
sing particle image velocimetry in a translucent test circuit
Fig. 3). The rotor was positioned along the center line of a
ransparent pump housing. The central part of the flow
hannel had an inner diameter of 6 mm and a divergent
ozzle at the downstream end to simulate outflow condi-
ions at the downstream end of the catheter. To reduce flow
isturbances upstream, a flow straightener and a contraction
ozzle were placed in the inflow chamber. A water-
lycerine mixture of 30% vol glycerine was used as a test
Abbreviations and Acronyms
CO  cardiac output
MAP mean aortic blood pressure
MIH  modified index of hemolysis
PFH  plasma-free hemoglobin
TEE  transesophageal echocardiographys
igure 1. Catheter pump with expanded pump housing (expanded diam-
ter, 6.5 mm; introduction diameter, 9-F).uid with a viscosity of 3.6 cP (similar to human blood at
7°C). A thin laser sheet was focused in axial planes, which
rossed the rotor blade at different angles during rotation.
mall fluorescent tracer particles were added to the fluid and
ecorded in the light sheet with a digital double-shutter
amera (PCO Optics, Munich, Germany). The motion of
he tracer particles was frozen by a double-pulse of the laser
nto two separate images of the camera and digitally
rocessed with cross-correlation methods to obtain the
ector field of velocity distribution.
nimal trials. The catheter pump was tested in 12 sheep
average body weight 73 kg). Approval for the study was
btained from the regional council in accordance with the
erman Animal Welfare Act. The animals were premedi-
ated with natriumpentobarbital (20 to 30 mg/kg intrave-
ously), intubated, and mechanically ventilated (isofluorane
.5 to 1.5%, supplemented with oxygen and N2O). Surface
lectrocardiographic leads were attached, and a gastric tube
nserted. All investigations were performed with the animals
n a supine position.
In 5 of the 12 sheep, pump delivery, deployment, and
peration, as well as the resulting hemolysis were tested. In
even of the animals, a 4-mm balloon catheter was placed in
he left anterior descending coronary artery and inflated to
nduce myocardial infarction (Fig. 4). For measurement of
ardiac output (CO), a Swan-Ganz catheter (131F7, Ed-
ards Lifesciences, Irvine, California) was inserted into the
ulmonary arteries. Measurements were performed in trip-
icate using ice-cold saline solution. Successful implemen-
ation of acute cardiac insufficiency was confirmed by a
igure 2. Schematic drawing of catheter pump position: expanded pump
ousing with inlet tip within the left ventricle, outlet tubing with the outlet
lits in the aortic root. The dark shadow within the pump body indicates
he position of the impeller.ubsequent reduction of CO.
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Expandable Percutaneous Catheter Pump June 7, 2005:1856–61Mimicking the clinical approach for the treatment of
cute myocardial infarction, systemic anticoagulation and
ntiplatelet therapy were provided. All animals received a
olus of 5,000 International Units (IU) unfractionated
eparin intravenously, followed by a continuous infusion
Figure 3. In vitro flow circuit for
igure 4. Spot film of the animal experimental set-up: 1) expanded
atheter pump in a transvalvular aortic position (white notched arrows); 2)
ip marker of the delivery sheath (thick white notched arrow); 3) inflated
alloon catheter in the left anterior descending coronary artery to provokeI
ardiogenic shock (thin white arrow); and 4) Swan-Ganz catheter in the
ulmonary artery for cardiac output measurement (black arrows).djusted to obtain an activated partial thromboplastin time
atio of 1.8 to 2.5. Subsequently, an intravenous bolus of
00 mg aspirin and 300 mg of clopidogrel were adminis-
ered orally. Following the Randomized Efficacy Study of
irofiban for Outcomes and Restenosis (RESTORE) pro-
ocol, we initiated glycoprotein IIb/IIIa inhibition (i.e., 10
g/kg bodyweight tirofiban over the course of 3 min
ollowed by a maintenance infusion of 0.15 g/kg/min) (5).
The catheter pump was inserted percutaneously via the
ight femoral arterial route, using a 9-F sheath that was 100
m in length. In the animals with myocardial infarction, the
ump was set into operation as soon as cardiac insufficiency
evidenced by a significant reduction of CO and presence of
achycardia) developed. Cardiac output and mean aortic
lood pressure (MAP) were recorded before and during
ardiac insufficiency and subsequently with catheter pump
upport. In six of the 12 animals, positioning of the pump in
elation to the aortic valve was monitored by TEE. At the
ompletion of the trial, the animals were killed, and the
earts and aortas were harvested, allowing the endocardium
nd aortic valve to be inspected macroscopically.
tatistics. Results are presented as mean values  SD. All
ariables were tested for normal distribution by the
olmogorov-Smirnov test. Repeated-measures analysis of
ariance was used for comparison of continuous and nor-
ally distributed data. A non-parametric test (Friedman
est) was applied to non-normally distributed data. Statistics
ere analyzed using SPSS 11.0 (SPSS Institute, Chicago,
l flow investigation of the pump.llinois).
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ench tests. Flow model tests revealed a maximum flow of
.1 l/min at 32,000 rpm with a differential pressure of 60
m Hg (Fig. 5). With an optimal rotor design, the average
IH was calculated as 11.6. By improving coaxial guidance
f the rotor within the housing, MIH was reduced to a
inimum value of 1.8. Maximum duration of rotation was
0 h.
low studies. The post-processing of measurement data
ielded velocity fields over different angular rotor positions.
n example of the flow structure in the central plane along
he flow axis (x-axis) is shown in Figure 6, indicating the
osition of the horizontal leading edge of the blade (phase
°). Velocity vectors show both flow direction and magni-
ude at the entrance of the rotor. Backflow was generated
pstream of the blade tip, in the gap between the rotor blade
dge and the housing. The main flow along the blade was
igure 5. Pump performance chart: flow versus pressure at operating
otation speed of 32,000 rpm.
igure 6. Instantaneous vector field of velocity distribution in the central p
otor diameter. The origin of the axis system is fixed with the leading edge of
bserved in fluid dynamics of turbines.ell directed axially over the complete blade surface. The
ownstream end of the rotor reveals a small flow separation
ear the rotor axis.
nimal trials. Fluoroscopically guided placement and de-
loyment in 12 sheep was straightforward and quick. Expan-
ion and rotation of the pump at 32,000 rpm was technically
easible. The correct pump position could be confirmed by
uoroscopy as well as by TEE. In seven animals, the model of
cute cardiac insufficiency worked well. Cardiac output de-
reased to 43  22% and MAP to 55  16% of the baseline
alue. With pump support, CO increased to 67  12% and
AP to 74  18% (Figs. 7 and 8).
Using TEE and color Doppler revealed no significant
itral valve insufficiency, aortic valve regurgitation, or
nsufficiency during pump support. Maximum in vivo
uration of pump operation was 6 h (average in 12
nimals, 3.1  1.4 h). There was no clinically significant
emolysis. Average baseline value of plasma-free hemo-
lobin (PFH) of 12 animals was 21  2 mg/l. After 30
in of pump action, PFH accounted for 25  5 mg/l,
nd after 3 h of pump action, 26  4 mg/l. With
ufficient anticoagulation and antiplatelet therapy, no
hrombotic deposits at the rotor, the pump housing, or
he drive shaft were observed.
Compression of the pump housing, by catheter with-
rawal into the delivery sheath and percutaneous removal of
he device, was simple and uneventful. Autopsy and inspec-
ion of heart and aorta did not show any macroscopic signs
f damage to the endocardium or aortic valve.
ISCUSSION
percutaneously insertable device for left ventricular sup-
ort must meet certain medical requirements, which prompt
t the entrance of the blade’s passage. Coordinates are normalized with thelane a
the rotor. The vortex structure indicates the typical tip clearance vortex
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Expandable Percutaneous Catheter Pump June 7, 2005:1856–61emanding technical solutions. To avoid complications at
he puncture site, the maximum introduction diameter is
imited to 9-F (3 mm). The pump unit had to be expandable
o provide for sufficient pump performance (a minimum
ow rate of 2.5 l/min with a differential pressure of 60 mm
g) at an acceptable rotation speed (in the range of 32,000
pm), with regard to drive shaft durability. Therefore, the
xpandable rotor and pump housing were the “critical”
echnical components. They required a sophisticated, dura-
le design that allowed for successful percutaneous position-
ng and deployment.
Our bench tests demonstrated that an expandable axial
ow pump is technically feasible. An adequate pump per-
ormance was achieved with a rotor diameter of 6 mm at a
otation speed of 32,000 rpm. A pump flow of more than 4
/min, at a mean pressure of 60 mm Hg, in a fluid with a
iscosity comparable with blood indicates its potential to
rovide for significant circulatory support in cardiac insuf-
ciency. The average in vitro hemolysis rate of the opti-
ized version is less than the MIH threshold of 20, which
s considered to be the upper limit for use of a blood pump
n a clinical setting (4).
Flow field study results showed the distribution of inflow
nd outflow velocity vectors. The lack of flow separation
long the expanded rotor blades emphasizes their well-
esigned profile. The backflow observed upstream of the
lade tip, in the gap between the rotor blade edge and the
ousing, is well known in turbine fluid dynamics as the tip
learance vortex. The small flow separation near the rotor
xis at the downstream end of the rotor is due to the positive
ressure gradient generated at the exit of the pump. Both
he clearance vortex and downstream flow separation are
nevitable side effects.
The results of our experiments on animals confirmed the
igure 7. Percentage cardiac output compared with baseline values (black
ar, n  7) depicted as mean values  SD after the induction of acute left
entricular (LV) failure without (white bar) and with pump support
striped bar). Significant changes between all time points (chi-square test
8.95, p  0.0001).roof of concept and indicate that the procedure is techni-
s
sally feasible and has the potential to be clinically beneficial.
ercutaneous fluoroscopy or TEE-guided pump delivery,
orrect placement, and removal were straightforward and
neventful. The pump performance under cardiac insuffi-
iency, as evidenced by CO and MAP measurements, was
onvincing. Transesophageal echocardiography images dur-
ng pump support showed neither significant impairment of
eft ventricular outflow nor induction of aortic valve insuf-
ciency. Additionally, TEE did not show any disturbance of
he mitral valve leaflets by the pump unit. Animal experi-
ental hemolysis rate (PFH 26  4 mg/l) was considerably
ess than the clinically significant threshold of 200 to 400
g/l. However, these promising results, obtained after an
verage support duration of 3.1 h, have to be confirmed in
urther trials of extended duration.
Despite a standard regimen of anticoagulation and plate-
et inhibition, no significant bleeding was observed. Fur-
hermore, no thrombotic deposits related to the pump unit
ccurred. By autopsy, no evidence of thrombus was found in
he heart and adjacent large vessels. However, assessment of
hromboembolic events by necropsy of other organs was not
erformed and will be the subject of further study.
Our device joins a growing assortment of miniaturized
xial flow rotary blood pumps. Blood pump design has a
istory of more than two decades, beginning with the
emopump in the late 1970s (6). None of these devices
eatured an expandable pump unit, other than the Reitan
ump, which was designed for operation in the descending
orta (7) and whose unconventional concept led to reduced
erfusion of carotid and coronary arteries, thus making it
nsuitable for the clinical setting.
A recently introduced, non-expandable axial flow pump
with a pump performance comparable with our device) is
he rotary blood pump by Impella (Aachen, Germany) with
n outer diameter of 6.4 mm (8). The use of the Impella
igure 8. Percentage mean aortic blood pressure compared with baseline
alues (black bar, n 7) depicted as mean values SD after the induction
f acute left ventricular (LV) failure without (white bar) and with pump
upport (striped bar). Significant changes between all time points (chi-
quare test 12.29, p  0.0003).
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June 7, 2005:1856–61 Expandable Percutaneous Catheter Pumpevice in 26 sheep with myocardial infarction revealed a
ignificantly reduced infarct size in the pump-supported
nimals. The pump produced a maximum CO of 4.1 l/min
nd significantly increased mean blood pressure. The reduc-
ion in infarct size correlated with the degree of “unloading”
uring reperfusion. In another study by Meyns et al. (9), the
ame device was applied in 16 patients with cardiogenic
hock. Cardiac output before support was 4.1 l/min and
ncreased by pump action to 5.5 l/min after 6 h and 5.9
/min after 24 h. However, 6 of 16 patients revealed a
emolysis rate of more than 1,000 mg/l PFH, and only 6 of
he 16 patients (37%) survived.
Stolinski et al. (10) addressed the interaction between the
ative heart and a rotary blood pump in a transvalvular
ortic position. Although a number of hypotheses were
enerated, none was experimentally proven. Neither the
oncept of “unloading” nor other aspects of preload and
fterload changes was explicitly tested.
tudy limitations. The goal of our study was to demon-
trate the feasibility of a new technical concept. Fluid
echanics of pump-heart interaction and investigation of
he effects of non-pulsatile flow generated by the pump in
onjunction with pulsatile flow of the heart for peripheral
rgan perfusion (e.g., kidney, liver, gut) initially were not
ddressed. Hemodynamic improvement as a result of pump
ntervention cannot rule out the possibility that recruitment
f collaterals may have contributed to observed positive
ffects. Further studies should be targeted to resolve these
ssues.
All examinations were performed in animals with healthy
ortic valves. Whereas aortic insufficiency would presumably
ot impair pump placement and ventricular support, it may
e complicated or impossible in case of severe aortic
tenosis. One major technical task still to be addressed is the
urther design optimization of our device. This will focus on
ncreasing the fatigue strength of the expandable compo-
ents to extend the in vivo operating period up to 72 h. This
uration would allow for a more effective bridging, e.g., in
ardiogenic shock after myocardial infarction.onclusions. The present study confirms the feasibility of
newly designed, percutaneous expandable blood pump in
itro and in vivo. Positioning, short-term results of pump
erformance and hemolysis rates were very encouraging.
he device could serve as a short-term mechanical support
n acute left ventricular failure, a concept that could meet
he requirements of contemporary interventional cardiology.
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